This did not occur until 2017, when, for the first time, NEK5 was shown to be overexpressed in an RNA-seq [134] analysis of Russian patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa), and this was further validated by RTqPCR. The gene discussed is NEK5; the disease is benign prostatic hyperplasia.